[Randomized controlled trials for the prevention and treatment of glucocorticoid-induced osteoporosis].
The effectiveness of drug therapy for the prevention or treatment of glucocorticoid-induced osteoporosis has been reported. Especially, the beneficial effects of bisphosphonates (etidoronate, alendronate, and risedronate) to prevent bone loss and fractures have been confirmed by the large-scale, multicenter, double-blind, randomized controlled trials in terms of both primary and secondary prevention. This article reviews the results of recent randomized prospective trials using bisphosphonates in glucocorticoid-induced osteoporosis.
Suzuki
Yasuo
Y
Tokai University School of Medicine, Department of Internal Medicine, Division of Rheumatology.
D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use*; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use; D010024:Osteoporosis / Q000139:chemically induced* / Q000188:drug therapy / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D011322:Primary Prevention; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D000068296:Risedronic Acid; D013739:Testosterone / Q000031:analogs & derivatives* / Q000627:therapeutic use
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D005938:Glucocorticoids; D006887:Hydroxycholecalciferols; D013739:Testosterone; D000068296:Risedronic Acid; C016131:testosterone 17 beta-cypionate; D012968:Etidronic Acid; C008088:alfacalcidol